Jeevan Scientific Technology Receives 'Hold' Rating

Jeevan Scientific Technology, a microcap pharmaceutical and drug company, has recently received a 'Hold' rating from MarketsMOJO. This upgrade is based on the company's strong ability to service its debt, with a low Debt to EBITDA ratio of 0.86 times.
Technically, the stock is currently in a bullish range and has shown improvement from a sideways trend on 28th December 2023. The MACD and Bollinger Band technical factors also indicate a bullish trend.

However, Jeevan Scientific Technology has shown poor long-term growth with an annual rate of -213.67% in operating profit over the last 5 years. In addition, the company's results for September 2023 were flat.

The stock is also considered risky due to its negative operating profits compared to its average historical valuations. In the past year, while the stock has generated a return of 6.23%, its profits have fallen by -157.1%.

Furthermore, Jeevan Scientific Technology has underperformed the market in the last 1 year, with a return of only 6.23% compared to the market's (BSE 500) return of 24.80%.

It is important for investors to carefully consider these factors before making any investment decisions regarding Jeevan Scientific Technology. While the company may have a strong ability to service its debt, its poor long-term growth and underperformance in the market may be cause for concern.